Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02570074
Previous Study | Return to List | Next Study

PK/PD and Safety/Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adults (PROOF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02570074
Recruitment Status : Completed
First Posted : October 7, 2015
Results First Posted : July 30, 2019
Last Update Posted : July 30, 2019
Sponsor:
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Vance Fowler, M.D., Duke University

Brief Summary:

Oral dosage regimens for fosfomycin tromethamine (Monurol™) are not established for the treatment of cUTI. The most common and recommended adult dosage regimen in the literature is a single-dose sachet containing the equivalent of 3 grams of fosfomycin administered every other day (QOD) for a total of three doses.

There are a myriad of different oral fosfomycin dosing regimens currently being used in clinical practice, including up to 3 grams orally twice daily for 7-21 days, but these regimens are not based on solid pharmacokinetic, pharmacodynamic or safety rationale. Initial pharmacokinetic studies performed with oral fosfomycin tromethamine primarily examined single dose regimens and did not use modern day bioanalytical or pharmacokinetic techniques. As the use of fosfomycin becomes more pervasive in concordance with the increase in multidrug resistant pathogens, further pharmacokinetic and safety data are needed for more intensive dosing regimens to support its continued use.

The rationale of this study is that oral fosfomycin tromethamine requires a modern pharmacokinetic-pharmacodynamic study to identify alternative oral dosage regimens that are appropriate and safe. This study provided safety/tolerability and clinical pharmacology information regarding two oral dosing regimens that may have application to treat various types of infections involving resistant pathogens or when other oral antibacterial options are not available.


Condition or disease Intervention/treatment Phase
Healthy Subjects Drug: Fosfomycin Phase 1

Detailed Description:

The study was designed as a randomized, two-way crossover trial involving up to 24 randomized participants with an anticipated drop-out rate no higher than 25% to give a total of 18 evaluable healthy adult participants. The study was fully explained to each participant, informed consent was obtained, and an IRB-approved informed consent form was signed before any study procedures were initiated. All participants underwent screening assessments within 30 days prior to the initial dosing to determine their eligibility for enrollment into the study. All participants met the inclusion and exclusion criteria and underwent screening procedures that included a complete medical history, physical examination, assessment of clinical laboratory parameters (chemistry and hematology), ECG, and pregnancy test (females of child bearing potential only).

Randomization was stratified by gender, using permuted blocks. Within each gender, eligible participants were randomized with equal probability to one of the 2 treatment sequences shown in Table 3. According to the sequence to which the participant was randomized, the participant initially received one of two oral dosage regimens of fosfomycin: 3 g every other day x 3 doses or 3 g once-daily x 7 doses. After completion of the initial dosing regimen each participant was crossed over to receive the other dosing regimen. There was a minimum 5-day, and a recommended maximum 14-day, washout period prior to starting the next dosing regimen. Blood and urine samples were collected throughout the study as well as detailed drug administration and adverse event data for each participant.

Fosfomycin tromethamine sachet (Monurol™) was used in this study. Each participant was instructed how to stir and dissolve the single-dose sachet into 3 to 4 ounces of water, and take each dose immediately after dissolving in water. Compliance was assessed by participant interviews (every 2 days) and counting of empty of sachets.

Participants reported to the outpatient study center on Day -30 to -1 for study criteria review, clinical assessment, and blood collection for screening laboratory tests prior to fosfomycin administration. Each participant participated in the study up to 120 days (i.e., screening visit; day -1 for clinical assessment and blood collection; days 1-7 for fosfomycin administration and sample collection period; and day 8-10 for follow-up assessment; crossed over to receive the other dosing regimen and schedule of events.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Phase I Study to Evaluate Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants
Actual Study Start Date : January 2016
Actual Primary Completion Date : September 2016
Actual Study Completion Date : November 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Fosfomycin - 3 doses QoD/7 doses QD
Fosfomycin given as a 3 gm dose, every other day for 3 doses, followed by 3 gm dose, once a day for 7 doses.
Drug: Fosfomycin
Broad spectrum antibiotic

Experimental: Fosfomycin - 7 doses QD/3 doses QoD
Fosfomycin given as a 3 gm dose, once a day for 7 doses, followed by 3 gm dose, every other day for 3 doses.
Drug: Fosfomycin
Broad spectrum antibiotic




Primary Outcome Measures :
  1. Number (%) of Grade 2 or Higher AEs Regardless of Relationship to Study Drug [ Time Frame: 3 months ]
  2. Day 1: Plasma PK Concentrations [mg/L] [ Time Frame: Day 1: 0, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours from dose ]
    Day 1 mean and standard deviation plasma concentrations [mg/L] at 0, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours from dose

  3. Day 5: Plasma PK Concentrations [mg/L] [ Time Frame: Day 5: 0, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours from dose ]
    Day 5 mean and standard deviation plasma concentrations [mg/L] at 0, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours from dose

  4. Maximum Plasma Concentration (Cmax) [ Time Frame: 24 hours ]
    To estimate the fosfomycin pharmacokinetic parameter maximum plasma concentration (Cmax) at steady-state for orally-dosed fosfomycin tromethamine in healthy adult participants

  5. Day 1: Area Under the Concentration Time Curve (AUC 0-infinity) [ Time Frame: 24 hours ]
    To estimate the fosfomycin pharmacokinetic parameter area-under-the-plasma concentration-time curve (AUC 0-infinity) at steady-state for orally-dosed fosfomycin tromethamine in healthy adult participants

  6. Day 5: Area Under the Concentration Time Curve (AUC Tau-infinity) [ Time Frame: 24 hours ]
    To estimate the fosfomycin pharmacokinetic parameter area-under-the-plasma concentration-time curve (AUC 0-tau) at steady-state for orally-dosed fosfomycin tromethamine in healthy adult participants

  7. Number of Subjects Who Prematurely Discontinue Study Drug [ Time Frame: Dosing period: 7 days ]

Secondary Outcome Measures :
  1. Total Body Clearance (CL) [ Time Frame: Pooled over 24 hours: Day 1 ]
  2. Apparent Volume of Distribution (Vss) [ Time Frame: Pooled over 24 hours at Day 1 and Day 5 ]
  3. Elimination Rate Constant (z) [ Time Frame: Pooled over 24 hours at Day 1 and Day 5 ]
  4. Elimination Half-life (t½) [ Time Frame: Pooled over 24 hours at Day 1 and Day 5 ]
  5. Renal Clearance (CLR) [ Time Frame: Pooled over 24 hours at Day 1 and Day 5 ]
  6. Amount Excreted in the Urine (Ae) [ Time Frame: Pooled over 24 hours at Day 1 and Day 5 ]
  7. Urinary Bactericidal (UBT) Titers for E. Coli ATCC 25922 [ Time Frame: 3 months ]
    UBT for E.coli ATCC 25922

  8. Urinary Bactericidal Kinetics (UBK) [ Time Frame: 3 months ]
  9. Urine Fosfomycin Concentrations [mg/L] [ Time Frame: Day 1: 24 hours ]
    Urine Fosfomycin concentrations [mg/L]

  10. UBT-time Curve (AUBT24) [ Time Frame: 24 hours at Day 1 and Day 5 ]
    For pathogens E. coli ATCC 25922, E. coli ATCC BAA-2323, K. pneumoniae ATCC 33495, K. pneumoniae ATCC 700603 and P. mirabilis ATCC 35659

  11. Urine Fosfomycin Concentrations [mg/L] [ Time Frame: Day 5: 24 hours ]
    Urine Fosfomycin concentrations [mg/L]

  12. Urinary Bactericidal (UBT) Titers for E. Coli ATCC BAA-2323 [ Time Frame: 24 hours on Day 1 and Day 5 ]
    UBT for E. Coli ATCC BAA-2323

  13. Urinary Bactericidal (UBT) Titers for K. Pneumoniae ATCC 33495 [ Time Frame: 24 hours on Day 1 and Day 5 ]
    UBT for E.coli K. Pneumoniae ATCC 33495

  14. Urinary Bactericidal (UBT) Titers for K. Pneumoniae ATCC 700603 [ Time Frame: 24 hours on Day 1 and Day 5 ]
    UBT for K. Pneumoniae ATCC 700603

  15. Urinary Bactericidal (UBT) Titers for P. Mirabilis ATCC 35659 [ Time Frame: 24 hours on Day 1 and Day 5 ]
    UBT for P. Mirabilis ATCC 35659

  16. Urinary Inhibitory (UIT) Titers for E. Coli ATCC 25922 [ Time Frame: 24 hours on Day 1 and Day 5 ]
    UIT for E.coli ATCC 25922

  17. Urinary Inhibitory (UIT) Titers for E. Coli ATCC BAA-2323 [ Time Frame: 24 hours on Day 1 and Day 5 ]
    UIT for E. Coli ATCC BAA-2323

  18. Urinary Inhibitory (UIT) Titers for K. Pneumoniae ATCC 33495 [ Time Frame: 24 hours on Day 1 and Day 5 ]
    UIT for E.coli K. Pneumoniae ATCC 33495

  19. Urinary Inhibitory (UIT) Titers for K. Pneumoniae ATCC 700603 [ Time Frame: 24 hours on Day 1 and Day 5 ]
    UIT for K. Pneumoniae ATCC 700603

  20. Urinary Inhibitory (UIT) Titers for P. Mirabilis ATCC 35659 [ Time Frame: 24 hours on Day 1 and Day 5 ]
    UIT for P. Mirabilis ATCC 35659



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. The participant is healthy as judged by the site investigator with no clinically significant abnormality identified on a medical evaluation including history, physical examination, laboratory tests, blood pressure, and heart rate.
  2. Male and female participants between 18 to 55 years old.
  3. Female participants of childbearing potential (not surgically sterilized and between menarche and one-year post-menopause) must have a negative pregnancy test at the time of enrollment and must agree to use appropriate contraception for as long as they are taking the study drug and for 1 month afterwards. During the screening visit, participants will be instructed to use a second reliable method of birth control in accordance with the protocol during the study and for one month following. Medically acceptable contraceptives include:

    • Surgical sterilization (such as a tubal ligation or hysterectomy)
    • Approved hormonal contraceptives (such as birth control pills, patches, implants or injections)
    • Barrier methods (such as a condom or diaphragm) used with a spermicide, or
    • An intrauterine device (IUD). i. NOTE: Contraceptive measures such as Plan B™, sold for emergency use after unprotected sex, are not acceptable methods for routine use.
  4. Nonsmokers defined as abstinence from cigarette smoking for the previous 6 months before enrollment into the study.
  5. Provide a signed and dated written informed consent prior to any study-specific procedures (including screening procedures).
  6. Body weight ≥50 kg
  7. Body mass index (BMI) 18.5-29.9 kg/m2

Exclusion Criteria:

  1. History of significant hypersensitivity reaction or intolerance to fosfomycin tromethamine that in the opinion of the site investigator, contraindicates participation in the study. In addition, if heparin is used during pharmacokinetic sampling, participants with a history of sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled.
  2. History of significant cardiac, neurological, thyroid, muscular, or immune disorder.
  3. Any laboratory abnormality grade 2 or higher as defined according to the U.S. Department of Health and Human Services common terminology criteria for AEs (CTCAE).26
  4. Estimated creatinine clearance (CLCR) <60 ml/minute as determined by Cockcroft-Gault equation
  5. Positive serum pregnancy test.
  6. Currently breast feeding.
  7. History of alcohol or substance abuse or dependence within 6 months of the screening: History of regular alcohol consumption averaging >7 drinks/week for women or >14 drinks/week for men. 1 drink is equivalent to 12g alcohol = 5 oz (150 mL) of wine or 12 oz (360 mL) of beer or 1.5 oz (45 mL) of 80 proof distilled spirits.
  8. The use of prescription (except birth control pills or hormone replacement in females) or non-prescription drugs, including herbal and dietary supplements (including St. John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of site investigator the medication will not interfere with the study procedures or compromise participant safety.
  9. The participant has participated in a clinical trial and has received a drug or a new chemical entity within 30 days prior to the first dose of study medication.
  10. Participants who have donated blood to the extent where participation in the study would result in excess of 500 mL blood donated within a 56 day period.
  11. Those who, in the opinion of the site investigator, have a risk of non-compliance with study procedures.
  12. QTc interval with Fredericia correction >450ms or any other clinically relevant ECG abnormalities

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02570074


Locations
Layout table for location information
United States, Illinois
University of Illinois at Chicago
Chicago, Illinois, United States, 60612
Sponsors and Collaborators
Vance Fowler, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Layout table for investigator information
Principal Investigator: Vance Fowler, MD Duke University
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Vance Fowler, M.D., Professor, Duke University
ClinicalTrials.gov Identifier: NCT02570074    
Other Study ID Numbers: Pro00066102
1UM1AI104681-01 ( U.S. NIH Grant/Contract )
First Posted: October 7, 2015    Key Record Dates
Results First Posted: July 30, 2019
Last Update Posted: July 30, 2019
Last Verified: July 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Fosfomycin
Anti-Bacterial Agents
Anti-Infective Agents